{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"DBP, any grade increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"SBP, any grade increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\\<120 mmHg, 120-139 mmHg\\[Grade 1\\], 140-159 mmHg\\[Grade 2\\], \\>=160 mmHg\\[Grade 3\\]); For DBP: \\<80 mmHg \\[Grade 0\\], 80-89\\[Grade 1\\], 90-99\\[Grade 2\\], \\>=100 mmHg\\[Grade 3\\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.","groups":[{"description":"Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (MM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 2 MM Population","reportingStatus":"POSTED","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)","title":"Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)","type":"PRIMARY","unitOfMeasure":"Participants"}